Theriva Biologics shares are trading higher after the company announced it will present preclinical data for the potential synergy of VCN-01 and first-line pancreatic cancer chemotherapy regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting.
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics' shares surged following the announcement of its plans to present preclinical data for VCN-01, in combination with first-line pancreatic cancer chemotherapy regimens, at the American Society for Cell and Gene Therapy 27th Annual Meeting.
April 22, 2024 | 9:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theriva Biologics' stock price increased after announcing the presentation of promising preclinical data for VCN-01 in pancreatic cancer treatment.
The announcement of presenting preclinical data for a potential treatment in a high-need area like pancreatic cancer is a strong positive signal for investors, likely leading to increased investor confidence and a rise in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100